Global Market Direct’s pharmaceuticals report, “Oragenics, Inc. - Product Pipeline Review - 2013” provides data on the Oragenics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Oragenics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Oragenics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
- Oragenics, Inc. - Brief Oragenics, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Oragenics, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Oragenics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Oragenics, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Oragenics, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Oragenics, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Oragenics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Oragenics, Inc.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Oragenics, Inc. and identify potential opportunities in those areas.
Table Of Contents
Oragenics, Inc. - Product Pipeline Review - 2013 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 3 Oragenics, Inc. Snapshot 4 Oragenics, Inc. Overview 4 Key Information 4 Key Facts 4 Oragenics, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 Oragenics, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Oragenics, Inc. - Pipeline Products Glance 10 Oragenics, Inc. Clinical Stage Pipeline Products 10 Phase I Products/Combination Treatment Modalities 10 Oragenics, Inc. - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Oragenics, Inc. - Drug Profiles 12 MU-1140 12 Product Description 12 Mechanism of Action 12 RandD Progress 12 MU-1140-S 13 Product Description 13 Mechanism of Action 13 RandD Progress 13 SMaRT Replacement Therapy 14 Product Description 14 Mechanism of Action 14 RandD Progress 14 Oragenics, Inc. - Pipeline Analysis 15 Oragenics, Inc. - Pipeline Products by Therapeutic Class 15 Oragenics, Inc. - Pipeline Products By Target 16 Oragenics, Inc. - Pipeline Products by Route of Administration 17 Oragenics, Inc. - Pipeline Products By Mechanism of Action 18 Oragenics, Inc. - Recent Pipeline Updates 19 Oragenics, Inc. - Company Statement 20 Oragenics, Inc. - Locations And Subsidiaries 24 Head Office 24 Other Locations and Subsidiaries 24 Appendix 25 Methodology 25 Coverage 25 Secondary Research 25 Primary Research 25 Expert Panel Validation 25 Contact Us 26 Disclaimer 26
List of Tables
Oragenics, Inc., Key Information 4 Oragenics, Inc., Key Facts 4 Oragenics, Inc. - Pipeline by Indication, 2013 7 Oragenics, Inc. - Pipeline by Stage of Development, 2013 8 Oragenics, Inc. - Monotherapy Products in Pipeline, 2013 9 Oragenics, Inc. - Phase I, 2013 10 Oragenics, Inc. - Preclinical, 2013 11 Oragenics, Inc. - Pipeline By Therapeutic Class, 2013 15 Oragenics, Inc. - Pipeline By Target, 2013 16 Oragenics, Inc. - Pipeline By Route of Administration, 2013 17 Oragenics, Inc. - Pipeline Products By Mechanism of Action, 2013 18 Oragenics, Inc. - Recent Pipeline Updates, 2013 19 Oragenics, Inc., Other Locations 24
List of Figures
Oragenics, Inc. - Pipeline by Indication, 2013 6 Oragenics, Inc. - Pipeline by Stage of Development, 2013 8 Oragenics, Inc. - Monotherapy Products in Pipeline, 2013 9 Oragenics, Inc. - Pipeline By Therapeutic Class, 2013 15 Oragenics, Inc. - Pipeline By Route of Administration, 2013 17